The initial trial would focus on dosage before expanding into psilocybin treatments for a variety of health conditions.
The information package included the investigational product’s chemical constituents, genotype, and formulation as well as procedures and processes to produce a consistent dosage from psilocybe mushrooms. “Numinus is pleased to partner with Optimi on this important work and provide the expertise, licensed facility and specialized equipment required to quickly develop, formulate and rigorously test products derived from natural psilocybe sources and prepare them for Health Canada submissions and approvals,” said Sharan Sidhu, science officer and general manager of Numinus Bioscience.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: globeandmail - 🏆 5. / 92 더 많은 것을 읽으십시오 »